Major Highlights for Month of February 2016

Share on LinkedIn

Indian Pharma Market (IPM) clocked 8139 Crs in February 2016 and grew at 12.0% for the month of February 2016

Companies: In the top 10 ranked cos, Mankind grew by 27.7%, Sun* by 19.3% & Lupin at 18.6% and 16 cos crossed the growth of IPM in the top 50

In the top 50 ranked cos, Bharat Serums has the highest growth of 36.3% followed by DRL at 32.5% & Mankind at 27.7%

23 cos grew more than 10% in the top 50 ranks

In the 11-20 ranked cos DRL has the highest growth of 32.5% followed by Intas at 22.5% & USV at 20.1%

In the top 21-30 ranked cos, Novartis has the highest growth at 16.7% followed by Ipca at 11.5% and Eris at 10.1%

In the top 31-40 ranked cos, Bharat Serums grew at 36.3% followed by JBCPL at 18.7% and Hetero at 11.8%

In the top 41-50 ranked cos, Systopic has the highest growth at 25.8% followed by Panacea at 13.8% & Wallace* at 13.0%

In the top 51-60 ranked cos, Boehringer grew at 57.1% followed by Fresenius Kabi at 32.2% & Corona at 16.3%

In the top 61-70 ranked cos, RPG grew at 25.4% followed by Shreya at 23.8%  and Geno at 19.0%

In the top 71-80 ranked cos, Samarth grew at 44.3% followed by Lincoln at 29.7% & Walter Bushnell at 23.2%

In the top 81 -90 ranked cos, Galpha grew at 48.7% followed by Veritaz at 37.5% and Dabur at 37.2%

In the top 91- 100 ranked cos, Gland grew at 34.9% followed by Serum Institute at 20.3% and Jenburkt at 18.8%                       

100th Biggest Corporate is Overseas and 150th Biggest Corporate is UTH 

Boehringer entered the 300 Cr Club and Samarth Life Sciences entered the 150 Cr Club,  on MAT Basis

Innovcare a new co makes its presence felt at 213th Rank with a turnover of 12 Crs in Feb 2016.

Indian Vs MNC: Indian cos grew at 14.0% Vs. 5.0% for MNCs in Feb 2016

In the top 50 ranked in MNCs, Novartis grew at 16.7% followed by Merck at 11.5% and Janssen at 9.6%

In the Non-NLEM category Indian Cos grew at 12.4% and MNCs at 1.1%

NLEM, Non NLEM & Non-Scheduled Para 19 Market:

NLEM containing molecules market grew at 6.9% whereas the non DPCO market grew by 12.9%  and Non -Sch Para 19 Market at 15.3% resulting in an overall growth of 12.0% for February 2016

NLEM and non-NLEM Category showed  unit growth a 3.4% and 3.3% respectively. The Non-Sch Para 19 Market grew at 9.1% from units perspective.

Therapy: 14 therapies have outgrown the IPM growth

Respiratory Market grew at 5.8%, Gastrointestinal market grew at 16.4% , Pain & Analgesics market grew at 9.7% whereas Anti-infectives grew at 5.3%

Anti-diabetic market grew at 18.1% and Cardiac at 17.3% in Chronic Business

Derma grew by 16.8% and Urology Market at 17.0%. Neuro/CNS at 18.9%

Regional Dynamics: 14 regions have outgrown the IPM growth

Odisha market grew the highest at 22.2%% followed by Punjab market at 20.8% and Vidarbha Market at 18.5%

No regions had negative growth in February 2016

 Molecules: Amoxycillin + Clavulanic Acid  market grew at 2.8% and Glimepiride + Metformin Market  grew at 19.3%

The markets of Paracetamol grew at 14.4%, Atorvastatin 11.7%, Probiotic Microbes at 39.7%, Cefixime -4.8%, Pantoprazole 17.6%, Montelukast + Levocetrizine at 7.0%, Glimepiride + Metformin + Pioglitazone at 19.1%, Vitamin-D at 22.0%, Hydroquinone + Mometasone + Tretinoin at 12.8%, Voglibose + Metformin + Glimepiride at 46.9%, Rosuvastatin at 22.8%, Protein Supplements at 6.9%, Azithromycin at -6.4%, Calcium Carbonate + Vit D3 market at -0.1%, Paracetamol + Phenylephrine + Chlorpheniramine at -4.6%, Meropenem at 48.3%, Montelukast + Fexofenadine at 22.6%, Diclofenac at 21.5%

50th Biggest Market is Voglibose + Metformin + Glimepiride and 100th Biggest Market is Levofloxacin

Brands: Mixtard leads the pack with 36 Crs followed by Glycomet GP and Augmentin at 28 Crs for February 2016. On MAT Basis Glycomet GP is ranked now at No 2.

Few Brands who have gained ranks include Unwanted Kit (+75), Meronem (+54), Electral Powder (+51), Aciloc RD (+32), Betnovate C (+29), Rabipur (+27), Mifegest Kit (+25), Voveran, Omez (+22), Telma (+21), Rosuvas, Vertin, Trajenta (+20), Thyronorm, Betnovate N, Rotarix, Aztor, Deriphylin (+18), Istamet (+17), Storvas (+16), Galvus Met, Jalra M, Levipil, Eltroxin, Atorva, Pantocid D SR, Cardace (+15), Gluconorm G (+14), Gemer, Susten, Duphalac (+13), Ultracet (+12), Pan, Synflorix, Budecort, Glycomet, Mucaine (+11), Rantac (+9), Orofer XT (+8), amongst top 100 Brands over February – 15

Lonopin, Razo D, Brilinta, Zerodol P, Enterogermina, Econorm, Zerodol P, Finecef, Metpure XL, Omez D  are few brands gained ranks in 101-200 ranked brands

Few Brands that have moved up ranks fastest into Top 300 Brands for the month of February – 16 are Revital H, Lonopin, Ocid, Similac, Candiforce, Razo D, Glimestar M, Brilinta, Gabapin NT

300th Biggest Brand is Reditux from DRL

New Launches in IPM: 224  Brands and 409 SKUs launched in Feb 2016

Top New Brands for February -16 are Pegclear, Azacytin, Epilyno

1 Brand Launched in Sofosbuvir + Ledipasavir category – Sofocruz LP from Torrent

In the VMS category we see GB 29 Total (Corona), Maxical Plus (Mankind) & Ensame (Icarus Healthcare)

In Anti-diabetic we see Glytrin (Medley), Glimipack M, Voglipack ( Koye)

In Respiratory  we see Acemont (Avis Life Care), Ranmotel C (Sun*), Vitaresp AB (Alembic)

In Anti – Infectives we see Tygaray ( Mylan), Sofocruz LP (Torrent) and Kartel (Saffron)

v  Within Cardiac we see Modlip D (Torrent), Benipack (Koye) & Supertel (Gland)

In Gastro we see Pegclear (Zuventus), Eco All Z (Hetero) and Glinzo D SR (Glenmark)

Biggest New Launch by a MNC is Tygaray in February 2016

Data Source: AIOCD Pharmasofttech AWACS